Loading...
Please wait, while we are loading the content...
Similar Documents
Immunotherapy Updates in Advanced Hepatocellular Carcinoma
| Content Provider | MDPI |
|---|---|
| Author | Singh, Amisha Beechinor, Ryan Huynh, Jasmine Li, Daneng Dayyani, Farshid Valerin, Jennifer Hendifar, Andrew Gong, Jun Cho, May |
| Copyright Year | 2021 |
| Description | Hepatocellular carcinoma (HCC) is the second most common cause of cancer death worldwide. HCC tumor development and treatment resistance are impacted by changes in the microenvironment of the hepatic immune system. Immunotherapy has the potential to improve response rates by overcoming immune tolerance mechanisms and strengthening anti-tumor activity in the tumor microenvironment. In this review, we characterize the impact of immunotherapy on outcomes of advanced HCC, as well as the active clinical trials evaluating novel combination immunotherapy strategies. In particular, we discuss the efficacy of atezolizumab and bevacizumab as demonstrated in the IMbrave150 study, which created a new standard of care for the front-line treatment of advanced HCC. However, there are multiple ongoing trials that may present additional front-line treatment options depending on their efficacy/toxicity results. Furthermore, the preliminary data on the application of chimeric antigen receptor (CAR-T) cell therapy for treatment of HCC suggests this may be a promising option for the future of advanced HCC treatment. |
| Starting Page | 2164 |
| e-ISSN | 20726694 |
| DOI | 10.3390/cancers13092164 |
| Journal | Cancers |
| Issue Number | 9 |
| Volume Number | 13 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-04-30 |
| Access Restriction | Open |
| Subject Keyword | Cancers Oncology Hepatocellular Carcinoma Immunotherapy Immune Checkpoint Inhibitors Pd-1 Pd-l1 Ctla-4 Chimeric Antigen Receptor |
| Content Type | Text |
| Resource Type | Article |
